Allergy Therapeutics has had its grass pollen allergy treatment Grassmuno approved in Germany, its first market, setting up a launch early next year.

A California biotech launched on Tuesday morning to try to bring a niche pain drug, approved in Italy for more than a decade, to the

Aeovian Pharmaceuticals has collected $55 million to see if it can prove its mTORC1 approach in tuberous sclerosis complex and consider getting into obesity with

RTW Investments is making a licensing deal with a China biotech for an antibody that’s being developed for two related autoimmune conditions called Graves’ disease

The FDA extended its review of Aldeyra Therapeutics’ dry eye disease drug reproxalap, after rejecting it twice before, to a new action date of March